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RESUMO
Evolução Clínica após Intervenção  
Coronária Percutânea em Indivíduos  
com Transplante Renal Prévio
Introdução: A doença arterial coronária é uma das princi-
paiscausas de óbito em pacientes com doença renal crônica. 
Alémdisso, em decorrência da elevada prevalência de fatores 
de risco para aterosclerose, muitos desses pacientes necessitam 
de intervenção coronária percutânea (ICP) mesmo após o trans-
plante renal. O objetivo deste estudo é descrever a evolução 
tardia de pacientes transplantados renais submetidos à ICP 
com stent. Métodos: Foram incluídos pacientes transplantados 
renais, com idade > 18 anos, tratados com ICP. O seguimento 
foi realizado por análise de prontuários e contato telefônico. 
O desfecho do estudo foi a incidência de eventos cardíacos 
adversos maiores (ECAM) durante o seguimento. Resultados: 
Foram incluídos 29 pacientes. A média de idade foi de 54,8 
± 8 anos, sendo a maioria do sexo masculino (72,4%). A 
prevalênciade hipertensão arterial sistêmica foi de 89,7%, de 
dislipidemia de 69%; e de diabetes, de 51,7%. A maior parte 
apresentava doença multiarterial (biarterial, 44,8%; triarterial, 
41,4%). A complexidade das lesões foi elevada, sendo 84,3% 
dos tipos B2 ou C e 27,5% com lesões em bifurcação. A taxa 
de sucesso do procedimento foi de 100%. Stents convencionais 
foram utilizados em 96,6% dos casos. O tempo de seguimento 
foi de 1.378 ± 977 dias. A mortalidade foi de 25,1%, a taxa 
ABSTRACT
Background: Coronary artery disease is a major cause of 
death in patients with chronic kidney disease. Moreover, 
due to the high prevalence of risk factors for atherosclero-
sis, many of these patients require percutaneous coronary 
intervention (PCI) even after renal transplantation. The aim 
of this study is to report the late follow-up of patients with 
renal transplantation treated with PCI and stenting. Methods: 
Patients > 18 years of age, with prior kidney transplantation, 
and treated with PCI were included. Clinical follow-up was 
evaluated by medical record analysis and telephone contact. 
The study endpoint was the incidence of major adverse car-
diac events (MACE) during follow-up. Results: Twenty-nine 
patients were included. Mean age was 54.8 ± 8 years and 
the majority male (72.4%). The prevalence of hypertension 
was 89.7%, dyslipidemia 69% and diabetes 51.7%. Most 
of them had multivessel disease (2-vessel: 44.8%; 3-vessel: 
41.4%). Lesion complexity was high, being 84.3% type B2 
or C lesions and 27.5% bifurcation lesions. Procedural suc-
cess rate was 100%. Bare metal stents were used in 96.6% 
of cases. The follow-up time was 1,378 ± 977 days. The 
mortality rate was 25.1%, target vessel revascularization 
rate was 15.9% and none of the patients presented non-
fatal infarction. The incidence of MACE during follow-up 
was 34.5%. Conclusions: Late follow-up after PCI in renal 
transplantation patients demonstrated a high probability of 
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clinical events. However, the study population was a sample 
of high clinical and angiographic complexity.
 
 
 
 
 
DESCRIPTORS: Angioplasty. Stents. Coronary disease. 
Kidney transplantation.
service. The research was based on the analysis of the 
database, medical records review, and telephone contact.
Study population
Between March 2002 and June 2011, 36 patients 
with prior renal transplantation were treated with PCI 
at the Instituto do Coração do Hospital das Clínicas, 
School of Medicine, Universidade of São Paulo (Incor/
HCFMUSP, São Paulo, SP, Brazil). Seven patients were 
excluded, as they did not have any new consultations 
recorded in their medical charts and it was not possible 
to complete the follow-up by telephone. A total of 29 
subjects comprised the final population of the analysis.
Procedure
Unfractionated heparin at a dose from70 U/kg 
to 100 U/kg was previously administered in all the 
procedures, aimed at obtaining activated clotting time 
between 250-300 seconds; the patients were receiving 
dual antiplatelet therapy with acetylsalicylic acid 100 
mg and clopidogrel 75 mg.
The choice of access route, techniques, and materi-
als, as well as diagnostic and intervention methods was 
made at the surgeon’s discretion. All cases received at 
least one bare-metal stent (BMS) or drug-eluting stent 
(DES) with diameters varying between 2.5 mm and 4 
mm. Angiographic success was considered with residual 
stenosis <  30% after PCI.
Data collection
Clinical and angiographic characteristics were ob-
tained from the database of the Service of He modynamics 
and Interventional Cardiology of InCor/HCFMUSP. In-
formation on the use of immunosuppressants was also 
assessed in each case.
The investigation of the events was performed using 
information obtained through medical record review and 
telephone contact. For cases in which the same event 
occurred more than once for the same patient, the re-
peated event was disregarded in the temporal analysis. 
The study outcome was the occurrence of major 
adverse cardiac events (MACE) during follow-up, defined 
de revascularização do vaso-alvo foi de 15,9% e nenhum 
paciente apresentou infarto não fatal. A incidênciade ECAM 
durante a evolução foi de 34,5%. Conclusões: A evolução 
clínica tardia após ICP em pacientes transplantados renais 
demonstrou elevada probabilidade de eventos clínicos. No 
entanto, a população estudada foi uma amostra de altacom-
plexidade clínica e angiográfica.
DESCRITORES: Angioplastia. Stents. Doença das coronárias. 
Transplante de rim.
T he increasing prevalence of chronic kidney dis-ease and consequent increased demand for renal replacement therapy has induced increased rates 
of renal transplantation worldwide.1 Only in Brazil, in 
the first half of 2012, 2,689 kidney transplantations 
were performed.2 In this context, there is an increased 
concern regarding this specific part of the population, 
aiming to identify their clinical peculiarities and to 
understand the comorbidities that develop over time.3
In recent years, chronic kidney disease has been 
confirmed as a condition very frequently associated with 
coronary artery disease, which is one of leading causes 
of death in patients who require substitutive therapy.4 
In a recent study of patients who underwent renal 
transplantation, after a period of 2.9 years, 32.8% had 
altered non invasive tests for assessment of myocardial 
ischaemia and 14.5% had angiographically significant 
lesions in the coronary angiography.5
In this scenario, percutaneous coronary intervention 
(PCI) has been increasingly used in renal transplantation 
patients, especially because it is a less invasive procedure 
when compared with the surgical alternative, following 
its specific indications. Moreover, in general, mortality 
between percutaneous and surgical revascularization 
alternatives is very similar in this population.6
Few studies have analyzed the long-term evolu-
tion of patients with prior renal transplantation treated 
with PCI and stenting. Research on this subject is of 
considerable interest, since it not only allows for the 
evaluation of the influence of classical risk factors for 
the development of coronary artery disease, but also 
for speculation on the impact of the characteristics 
of renal transplantation recipients, including the use 
of already tested immunosuppressive drugs to reduce 
intrastent restenosis.7-9
This study aimed to describe the late evolution in 
patients with a history of renal transplantation submit-
ted to PCI with stenting.
METHODS
This was a retrospective, single-center study, con-
ducted at a tertiary care, high-complexity cardiology 
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as death from any cause, acute myocardial infarction, 
and target vessel reintervention.
Statistical analysis
Analysis of the clinical and angiographic data was 
performed using the SPSS software (IBM Corp. – New 
York, United States). Continuous variables were described 
as mean and standard deviation, while categorical vari-
ables were described as frequencies and percentages. 
The event rate was estimated by Kaplan-Meier method.
RESULTS
The mean age was 54.8 ± 8 years and most of 
the subjects were males (72.4%). The prevalence of 
hypertension was 89.7%; dyslipidemia, 69%; diabetes, 
51.7%; and previous or current history of smoking, 
48.3%. The clinical picture that motivated the PCI 
was, in most cases, acute coronary syndrome without 
ST-segment elevation, observed in 55.2% of cases, fol-
lowed by acute coronary syndrome with ST-segment 
elevation in 27.6%. All others were diagnosed with 
stable angina (Table 1).
On average, patients had 6 ± 6 years since the 
transplantation. The prescription of immunosuppressants 
was available for 23 patients, and the drugs most often 
prescribed were mycophenolate (56.5%), prednisone 
(47.8%), and tacrolimus (39.1%) (Table 1).
Most cases had a multivessel obstructive pattern 
(two-vessel, 44.8%; three-vessel, 41.4%). Lesion com-
plexity was high; 79.3% were type B2 or C lesions, and 
27.5% involved bifurcations lesions,24.1% lesions with 
thrombus, and 17.2% ostial lesions. De novo lesions 
were treated in all cases. BMS were used in 96.6%of 
the cases, and angiographic success was attained in 
100% of cases (Table 2).
The meantime of follow-up after PCI was 1,378 ± 977 
days. During this period, 34.5% of patients had at least 
one MACE. The incidence of adverse events occurred 
throughout the study period (Fig. 1). Mortality during 
follow-up was 25.1%. None of the patients had non-
fatal acute myocardial infarction in the period, and 
15.9% required target vessel reintervention.
DISCUSSION
According to previous studies, the incidence of 
coronary atherosclerosis substantially higher in renal 
transplantation patients than in the general popula-
tion.10 Moreover, the risk for development of coronary 
artery disease is high, even before the progression to 
end-stage renal disease.11
This study evaluated the long-term evolution of 
patients treated with PCI and stenting in this specific 
population of transplanted patients. The authors consider 
the research relevant, as it allows for a better evaluation 
TABLE 1  
Clinical characteristics
Variable n = 29
Age, years 54.8 ± 8
Male gender, n (%) 21 (72.4)
Diabetes 15 (51.7)
Systemic arterial hypertension, n (%) 26 (89.7)
Dyslipidaemia, n (%) 20 (69)
Smoking, n (%) 14 (48.3)
Family history of early coronary artery 
disease, n (%)
2 (6.9)
Previous stroke, n (%) 1 (3.4)
Peripheral vascular failure, n (%) 2 (6.9)
Previous acute myocardial infarction, n (%) 3 (10.3)
Previous percutaneous coronary 
intervention, n (%)
3 (10.3)
Previous coronary artery bypass graft 
surgery, n (%)
4 (13.8)
Clinical picture, n (%)
Stable angina 5 (17.2)
Acute coronary syndrome without  
ST-segment elevation
16 (55.2)
Acute coronary syndrome with  
ST-segment elevation
8 (27.6)
Immunosuppressants n = 23
Tacrolimus 9 (39.1)
Cyclosporine 4 (17.4)
Mycophenolate 13 (56.5)
Sirolimus 1 (4.3)
Azathioprine 0
Prednisone 11 (47.8)
of the results of percutaneous treatment in patients with 
such particular characteristics, through the analysis of a 
significant sample of patients with these characteristics.
The occurrence of MACE in approximately one-
third of patients over a period of more than three years 
indicates that, even with partial renal function or fully 
recovered, the sample reflects a population at high risk 
for developing severe events.12
Considering that only one study patient was treated 
with DES, where as all the others were treated with 
BMS (96.6%), the need for target vessel reintervention 
in 15.9% of cases was an interesting result. In the 
general population, intrastent restenosis (which results 
from excessive neointimal proliferation after BMS im-
plantation)occurs in 20% to 30% of cases, determining 
higher rates of target vessel reintervention than those 
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observed in the present study.13-15 This result may be 
associated with a potential benefit of the immunosup-
pressive therapy, reaffirming what has been suggested 
in previous studies7-9,16 
During the follow-up period,in one-quarter of 
the patients, mortality from all causes was the major 
component of the high occurrence of MACE. This high 
death rate is expected in this population group, since, 
in addition to the high underlying cardiovascular risk, 
the impaired immune capacity (caused by the chronic 
kidney disease itself and the use of immunosuppressants) 
is associated with a higher risk of developing severe 
comorbidities, such as infections and malignancies, 
which are potentially life-threatening.3,17
Study limitations
The study has some limitations, including the fact 
that it was retrospective, based on information obtained 
from a database and medical records, as well as telephone 
contact, which was not possible in all cases. There was, 
therefore, loss of a non-negligible portion of patients who 
could not be included the final analysis. Moreover, the 
inclusion of patients who had their procedures performed 
at very different times, especially in an area of cardiology 
in which there are constant advances in the methods, 
materials, and medications, caused some individuals to 
receive slightly differentiated treatment.
CONCLUSIONS
In the present study, late clinical outcome after 
PCI in renal transplantation patients showed a high 
likelihood of clinical events. However, the population 
studied was a sample of high clinical and angiographic 
complexity. The rate of target vessel revascularization 
was reduced, but this finding needs to be better evalu-
ated in studies with larger sample sizes.
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major adverse cardiac events; ICP, percutaneous coronary intervention.
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